In contrast, in PS19 models where the R47H variant was introduced via bacterial artificial chromosome technology, investigators observed reduced tau pathology, attenuated synaptic loss, and decreased brain atrophy, accompanied by diminished inflammatory responses [105]. The gene discussed is MAPT; the disease is Brain atrophy.